And so there is a lot of flexibility that we have, and that’s I think a kind of a great place to be when you have kind of a growing and relevant scale, a strong balance sheet. And sort of all the engines are firing on all cylinders, you can establish good baseline and preserve some optionality.
Yigal Nochomovitz: Got it.
Josh Smiley: Hey, Billy, I’ll just maybe add, just one quick point to that is, really our priorities are to grow the top line and to advance our clinical programs, and we’ve got a plethora of them. But if we execute on those two priorities, Yigal, the profitability is going to follow. So, if you look at products like ZEJULA and our women’s health franchise, and the expected growth over the next few years and then add TIVDAK on top of that, those are the things that are going to drive profitability and give us the flexibility that Billy mentioned. We continue to invest in sales force, continue to invest in the clinical program. So again, to us it’s more around portfolio that we built. If we execute as we expect to along that side, the profitability is going to come.
Yigal Nochomovitz: And just real fast, just one housekeeping on QINLOCK and NUZYRA. So can we say at this point what the discount is for the NRDL? I think you mentioned the press release, you expect significant increase, just kind of just for modeling purposes, what does that look like? Thanks.
Billy Cho: Yes, so the NRDL pricing for QINLOCK is $2,400 a month. And then for NUZYRA, it’s $450 a month.
Yigal Nochomovitz: Okay.
Billy Cho: Oh, sorry for NUZYRA, it will be for the treatment, the $450 million — $450 for the treatment costs.
Yigal Nochomovitz: Okay, great. Thanks.
Operator: Thank you for your question. We are now taking the next question. Please stand by. The next question from Jonathan Chang from SVB Securities. Please go ahead. Your line is open.
Jonathan Chang: Hi, guys. Thanks for taking my questions. First question just to, can you elaborate more on the assumptions underlying your guidance of achieving corporate profitability by end of 2025 and discuss your level of confidence in this? And then second question, can you discuss Zai Lab’s current state of compliance with the HFCAA and how you’re thinking about the situation going forward? Thank you.
Josh Smiley: Yes, thanks, Jonathan. So I can take these two. And maybe I’ll start with the second one, that’s got to be a quick point that I want to make. So you would have seen that our 10-K that we just filed is with KPMG U.S. And that means that we have five things that are fully accessible by the PCAOB . And as a result, we have and continue to believe that we are now fully compliant with all the requirements of the HFCAA. And that’s going to preclude us from now and the future to be all sort of any kind of list or any kind of potential for delisting from the NASDAQ. So very proud of the team that worked hard to get this done. And it was strategically very important for us. So I think, again, a little kudos to the team and welcoming KPMG U.S on board.
So to your first question, on kind of how do we feel about the statement that we made about getting to an overall profitability by end of ’25? Jonathan, we wouldn’t make such statements, unless we’ve carefully thought about it. So the best way to think about — we’re not giving guidance at this time, so we’re not going to kind of give you hard numbers. But if you took your — the number that you had for 2025, whether you Jonathan, or whether the Street, and I know, there’s a range out there, but you take that, and you assume even if you assume just today’s gross profit, and that’s going to continue to improve over the next several years, but use that. And then you kind of stick with sort of the modest assumptions on sales, marketing, and G&A, especially since we would have already done a lot of heavy lifting infrastructure spend by then you will be able to get that.
